For pharmaceutical registration in Korea, the Ministry of Food and Drug Safety (MFDS) requires comprehensive clinical trial data. This includes preclinical findings, phase I-III trial results, safety profiles, efficacy evidence, and pharmacokinetic studies. Meeting MFDS guidelines ensures the drug’s safety, efficacy, and quality for the Korean population.
